ARTICLE | Clinical News

D2E7: Phase II data; Phase III

November 6, 2000 8:00 AM UTC

Additional data from CAT and partner BASF Pharma's 284-patient European Phase II trial of D2E7 showed that weekly subcutaneous doses of 20, 40 or 80 mg of D2E7 gave a sustained reduction in the signs ...